KALA Bio enters $375k convertible loan; Oxford pauses foreclosure, company faces cash crunch

KALA BIO, Inc.

Convertible loan of up to $375k from individual investor; first $187.5k due Nov 10, remainder by Nov 12, 2025.
Loan bears 15% simple interest; lender can convert into common stock at defined prices.
Proceeds limited to negotiating further investment with lender and preparing Q3 2025 Form 10-Q.
Oxford paused asset foreclosure on Nov 3. If no additional financing, foreclosure expected to resume.
Company cannot seek alternative offers from others until Nov 17, 2025; warns of going-concern risk.

item 1.01 item 2.03 item 3.02 item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-108844
form_type: 8-K
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2025-11-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.495143+00:00
generated_at: 2026-05-16T22:20:37.660298+00:00
sec_items: ["1.01", "2.03", "3.02", "8.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.78
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-108844
json_url: https://secwatch.observer/filing/0001104659-25-108844.json
markdown_url: https://secwatch.observer/filing/0001104659-25-108844.md
text_url: https://secwatch.observer/filing/0001104659-25-108844.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465925108844/0001104659-25-108844-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465925108844/kala-20251109x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-108844

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.